Answers are grounded in this paper and cite their sources.
Background Agalsidase beta is an enzyme replacement therapy for Fabry disease (FD) administered as a 1 mg/kg biweekly infusion over 90–120 minutes. The present study evaluated the safety and tolerability of a shortened 20-minute infusion duration, with pharmacokinetic simulations conducted to assess systemic exposure at accelerated infusion rates. Methods The SHORTEN study (NCT06019728) was a phase 4, prospective, open-label, single-arm trial. Eight patients were enrolled (5 male, 3 female; age 19–62 years) with confirmed diagnosis of FD, body weight ≥ 30 kg, and history of agalsidase beta therapy for ≥3 months without infusion-associated reactions (IARs). Infusion duration was progressively reduced by 20- or 30- minute increments until reaching 20 minutes, using a standardized 100 mL infusion volume. Primary endpoints were percentage reduction in infusion duration versus baseline and the shortest tolerated duration. Secondary endpoints included the proportion of patients achieving the shortest planned duration without IARs. A linear two-compartment model was developed using clinical trial data (21 patients; 1547 samples) for population pharmacokinetic (PopPK) simulation analysis. Simulations included 1 mg/kg dosing with 20- versus 120-minute infusion durations in 1,000 virtual participants. Maximum plasma concentration (C max ) and area under the curve (AUC) were evaluated within 24-hours after each dose. Results All participants achieved 20-minute infusion duration (median reduction 84.2%; IQR: 80.6%–86.3%) with no IARs reported. Treatment-emergent adverse events of moderate intensity were reported in two participants, with none considered treatment-related. Globotriaosylsphingosine levels (lyso-GL-3) remained stable, except for a transient small increase in one patient after a missed infusion. One participant had pre-existing low-titer anti-drug antibodies (ADAs), without any treatment-induced or treatment-boosted ADA responses observed. PopPK simulations demonstrated that shortening the infusion duration from 120 to 20 minutes approximately doubled the C max (8.18 vs. 3.86 μg/mL), while preserving equivalent AUC (857.02 μg/mL×min). Conclusions The SHORTEN study demonstrated that agalsidase beta can be safely administered over 20 minutes in carefully selected, treatment-experienced patients with FD. PopPK simulations support the acceptability of the shortened infusion duration, indicating comparable overall drug exposure with a clinically acceptable peak concentration profile. This accelerated infusion approach has the potential to reduce treatment burden while maintaining tolerability and therapeutic activity. Trial registration number ClinicalTrials.gov, NCT06019728. Registered 25 August 2023, https://clinicaltrials.gov/study/NCT06019728
No takes yet. Share an insight, caveat, or question.
Banikazemi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: